GHRP-2 vs GHRP-6 vs Ipamorelin: Growth Hormone Secretagogues Compared
GHRP-2, GHRP-6 and Ipamorelin all act on the same receptor, the ghrelin receptor (GHS-R1a), and all three trigger growth hormone release in research models. They are not interchangeable. They differ in potency, in how selective they are, and in which other hormonal pathways they disturb along the way. This guide sets out those differences so you can match the compound to the question your study is asking.
At a glance
| GHRP-2 | GHRP-6 | Ipamorelin | |
|---|---|---|---|
| Structure | Hexapeptide | Hexapeptide | Pentapeptide |
| Receptor | GHS-R1a (ghrelin receptor) | GHS-R1a | GHS-R1a |
| Relative GH-release potency in published models | High | Moderate–high | Moderate |
| Effect on cortisol and prolactin | Noticeable | Noticeable | Minimal in published models |
| Appetite-related ghrelin signaling | Present | Pronounced | Low |
| Typical research role | Potent reference agonist | Ghrelin and feeding-pathway studies | Selective GH-axis studies |
The shared mechanism
All three are growth hormone secretagogues: synthetic compounds that mimic ghrelin at the GHS-R1a receptor in the pituitary and hypothalamus. Activating that receptor triggers growth hormone release through a different route from GHRH (growth hormone-releasing hormone), which acts on its own receptor. That is why secretagogues are often studied alongside GHRH analogues such as CJC-1295 or Tesamorelin.
GHRP-6: the early benchmark
GHRP-6 was one of the first synthetic ghrelin-receptor agonists described, and much of the field’s early literature is built on it. In research models it reliably triggers GH release, and it is known for a strong effect on appetite-related ghrelin signaling. That makes it useful in feeding-behavior and ghrelin-pathway studies, and a confounding factor in studies that want to isolate GH effects. View GHRP-6.
GHRP-2: the potent reference agonist
GHRP-2 (pralmorelin) is among the most potent compounds in the family and is widely used as a reference agonist when researchers want a strong, consistent GH response. The trade-off is selectivity: published models show accompanying rises in cortisol and prolactin. Studies comparing secretagogues often use GHRP-2 as the high-potency benchmark. View GHRP-2.
Ipamorelin: the selective option
Ipamorelin was developed later with selectivity in mind. In published models it produces GH release with little measurable effect on cortisol or prolactin, and a weaker effect on appetite signaling than GHRP-6. When a study needs to attribute an outcome to GH-axis activation rather than to stress or prolactin pathways, Ipamorelin is usually the cleaner tool. See the Ipamorelin research profile for details.
Choosing between them
Maximum GH response or a reference standard: GHRP-2.
Ghrelin, appetite or feeding-pathway research: GHRP-6.
GH-axis effects with the fewest off-target hormone changes: Ipamorelin.
Comparing GHRH and ghrelin-receptor pathways: pair a secretagogue with a GHRH analogue, or use the pre-measured CJC-1295 + Ipamorelin blend.
Many comparison studies run all three side by side to map how selectivity and potency trade off within a single model.
Quality matters more with similar compounds
Because these peptides are close in structure, mislabeling or contamination with a related sequence is a real risk with low-quality suppliers. Mass-spectrometry identity testing confirms the molecular weight matches the compound on the label. Every lot we sell is tested by Bioviridian Labs (ISO/IEC 17025, Texas) for HPLC purity, mass-spec identity, endotoxin and heavy metals; look up any lot in the COA Library.
Shop growth factor research peptides →
For laboratory research use only. Not for human or veterinary use. This article summarizes published research for educational purposes and does not provide medical advice.